Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Side-Effect Profile Head-to-Head

Two Drugs, Two Mechanisms, Two Side-Effect Signatures

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist. Pioglitazone is a thiazolidinedione (TZD) that activates peroxisome proliferator-activated receptor gamma (PPARγ). These distinct mechanisms explain why their side-effect profiles barely overlap. Resmetirom mimics thyroid hormone action selectively in the liver, increasing hepatic fat oxidation and reducing lipotoxicity without the cardiac or bone effects of systemic thyroid hormone excess 1. Pioglitazone improves insulin sensitivity across adipose tissue, muscle, and liver, but PPARγ activation in fat and bone progenitor cells produces the weight gain, edema, and skeletal effects that have limited its adoption for MASH 2.

No randomized head-to-head trial has compared these two drugs directly. Every comparison below is drawn from cross-trial analysis of MAESTRO-NASH (resmetirom, N=966, 52 weeks) and PIVENS (pioglitazone, N=247 in the pioglitazone arm, 96 weeks), with the limitations that entails: different patient populations, different endpoints, and different durations 1 2.

Gastrointestinal Effects: Resmetirom's Primary Burden

GI symptoms are the most frequent adverse events with resmetirom. They are generally mild and they fade. In MAESTRO-NASH, diarrhea occurred in 33% of patients receiving the 80 mg dose versus 19% on placebo. Nausea affected 22% versus 13% on placebo. Most episodes were grade 1 and concentrated in the first 4 to 12 weeks of therapy 1.

Pioglitazone, by contrast, is not typically associated with significant GI disturbance. In PIVENS, GI adverse events occurred at rates comparable to placebo 2. This difference matters for patients who already have GI comorbidities or who take other medications that cause nausea (GLP-1 receptor agonists being the obvious example). Clinicians stacking resmetirom with semaglutide should anticipate compounded nausea risk in the first month and may consider staggered initiation.

The clinical significance of resmetirom's GI profile is limited by its transience. A 2024 post-hoc analysis of MAESTRO-NASH data showed that among patients who reported diarrhea, 78% experienced resolution by week 12 without dose adjustment 1.

Weight and Body Composition: Opposite Directions

This is the starkest difference between the two drugs. Pioglitazone causes weight gain. That is a pharmacologic certainty, not a side effect limited to predisposed patients. In PIVENS, subjects on pioglitazone 30 mg gained a mean of 4.7 kg over 96 weeks versus 0.2 kg in the placebo group 2. Much of this weight is subcutaneous adipose expansion driven by PPARγ-mediated adipogenesis. Some clinicians frame this as metabolically "healthy" fat redistribution (visceral to subcutaneous), but for patients already carrying excess weight, an additional 4 to 5 kg is rarely welcome.

Resmetirom moves weight in the opposite direction. In MAESTRO-NASH, the 80 mg group lost a mean of 1.6 kg more than placebo at 52 weeks, likely reflecting increased hepatic and systemic lipid oxidation from THR-β activation 1. The weight loss is modest, not comparable to GLP-1 agonists, but it represents a fundamentally different metabolic direction.

For patients with MASH and a BMI above 35, the weight trajectory alone may favor resmetirom or a resmetirom-plus-GLP-1 combination over pioglitazone monotherapy. For lean MASH patients (BMI <25), where insulin resistance is the dominant driver, pioglitazone's insulin-sensitizing action may outweigh the modest weight gain.

Edema and Cardiovascular Considerations

Peripheral edema is a class effect of thiazolidinediones. Pioglitazone causes fluid retention through PPARγ-mediated sodium reabsorption in the renal collecting duct. In PIVENS, edema occurred at notably higher rates in the pioglitazone group, and the drug carries a boxed warning against use in NYHA Class III or IV heart failure 2 3.

Resmetirom has shown no signal for edema or heart failure exacerbation. THR-β agonism actually lowers LDL cholesterol (mean reduction of 14 to 22% versus placebo) and lipoprotein(a), a finding that has generated interest in potential cardiovascular benefit 1. A cardiovascular outcomes trial for resmetirom has not been completed, so the lipid improvements remain a surrogate marker without confirmed event reduction.

The PROactive trial (N=5,238) demonstrated that pioglitazone reduced the composite of all-cause mortality, non-fatal MI, and stroke by 16% in patients with type 2 diabetes 4. This cardiovascular benefit is real and proven, but it was established in a diabetic population, not a MASH-specific cohort. The trade-off is genuine: pioglitazone has proven CV event reduction at the cost of fluid retention and heart failure risk, while resmetirom has favorable lipid effects without long-term outcomes data.

Bone Health: Pioglitazone's Underappreciated Risk

TZDs shift mesenchymal stem cell differentiation toward adipocytes and away from osteoblasts. The clinical consequence is measurable bone density loss and increased fracture risk, particularly in women. In the PROactive extension and observational data, pioglitazone use was associated with a 1.5 to 2-fold increase in distal extremity fractures in women over 2 to 3 years of exposure 3 5.

Resmetirom has shown no bone safety signal. THR-β is minimally expressed in bone, and unlike THR-α (which mediates thyrotoxic bone loss), selective THR-β agonism does not appear to accelerate bone turnover 1. For postmenopausal women with MASH, this distinction carries real clinical weight. A patient with osteopenia and biopsy-confirmed MASH faces a direct conflict if offered pioglitazone; resmetirom sidesteps that conflict entirely.

Hepatic and Gallbladder Safety

Both drugs require hepatic monitoring, but for different reasons. Pioglitazone carries a legacy warning about hepatotoxicity inherited from the troglitazone era, although pioglitazone-specific liver injury is extremely rare. The AASLD practice guidance notes that pioglitazone can be used in compensated MASH without significant hepatotoxic risk 6.

Resmetirom's label includes a warning about gallbladder-related events. In MAESTRO-NASH, cholelithiasis occurred in approximately 3% of the 80 mg group versus 0.8% placebo. One case of cholecystitis led to cholecystectomy 1. The mechanism likely involves THR-β-mediated increases in hepatic bile acid synthesis and cholesterol secretion into bile. Patients with a history of gallstones or cholecystectomy should be counseled about this risk. The FDA label recommends monitoring for gallbladder symptoms 7.

ALT elevations above 5 times the upper limit of normal occurred in 0.4% of resmetirom-treated patients, versus 0.4% on placebo, a non-signal. Resmetirom actually reduced ALT by a median of 28% from baseline, consistent with its hepatic mechanism of action 1.

Bladder Cancer Concern: Pioglitazone's Lingering Question

A 2016 BMJ meta-analysis (N=1,015,220 across 16 studies) reported a modest but statistically significant association between pioglitazone and bladder cancer risk (OR 1.17, 95% CI 1.03 to 1.33), with risk increasing with cumulative dose and duration exceeding 2 years 8. France and Germany pulled pioglitazone from their markets over this concern. The FDA reviewed the same data and opted to keep pioglitazone available with a label warning rather than a withdrawal.

The absolute risk is small. For a prescriber managing MASH in a patient with a personal or family history of bladder cancer, though, it becomes decision-relevant. Resmetirom carries no oncologic signal in trial data to date, though post-marketing surveillance periods remain short given the March 2024 approval.

Drug Interactions and Monitoring Burden

Pioglitazone is metabolized by CYP2C8 and CYP3A4. Strong CYP2C8 inhibitors (gemfibrozil) significantly increase pioglitazone exposure, and the combination is not recommended 3. Pioglitazone also requires periodic monitoring of liver enzymes and awareness of heart failure symptoms. Bone density monitoring is advisable for postmenopausal women on long-term therapy.

Resmetirom's interaction profile is narrower. It is a substrate of CYP2C8 and CYP3A4 but has fewer clinically significant interactions documented to date. The FDA label recommends against use in patients with moderate to severe hepatic impairment (Child-Pugh B or C) and specifies baseline and periodic liver function testing 7. Thyroid function monitoring (TSH, free T4) is recommended at baseline and periodically, particularly because selective THR-β agonism can suppress TSH via central feedback without causing clinical hyperthyroidism.

Dr. Arun Sanyal, principal investigator of the MAESTRO-NASH trial, stated: "The side-effect profile of resmetirom is predominantly gastrointestinal and generally manageable. The absence of weight gain and edema distinguishes it from the thiazolidinedione class" 1.

Discontinuation Rates and Real-World Tolerability

In MAESTRO-NASH, 5.4% of the 80 mg resmetirom group and 2.6% of the 100 mg group discontinued due to adverse events, versus 2.3% on placebo. The most common reason for discontinuation was GI intolerance 1.

In PIVENS, approximately 7% of the pioglitazone group discontinued for adverse events, with weight gain and edema cited as primary reasons 2. Cross-trial comparison is imperfect (different durations, populations, and thresholds for discontinuation), but both drugs show tolerability adequate for chronic use in the majority of patients.

Real-world adherence data for resmetirom is limited given its recent approval. Pioglitazone has decades of post-marketing experience, and adherence is often limited not by acute side effects but by progressive weight gain that accumulates over months to years.

Who Gets Which Drug: Clinical Decision Points

The AASLD 2023 practice guidance recommends pioglitazone for patients with biopsy-confirmed MASH who have type 2 diabetes or prediabetes, regardless of whether they have cirrhosis 6. Resmetirom is approved for non-cirrhotic MASH with moderate to advanced fibrosis (F2-F3), in combination with diet and exercise.

Dr. Mary Rinella, first author of the 2023 AASLD guidance, has noted: "Pioglitazone remains a valuable option when cost is a barrier, but clinicians must weigh the metabolic trade-offs, particularly weight gain and bone effects, against its proven histological benefit" 6.

Side-effect-driven decision points:

• Patient with MASH, BMI 38, no diabetes: Resmetirom preferred. Pioglitazone's weight gain is counterproductive.
• Patient with MASH and type 2 diabetes, normal BMI: Pioglitazone may be preferred. Insulin sensitization addresses the root metabolic defect, and weight gain from subcutaneous fat expansion is more tolerable at lower BMIs.
• Postmenopausal woman with MASH and osteopenia: Resmetirom preferred. Pioglitazone's bone effects are a direct contraindication to the patient's skeletal health.
• Patient with MASH and NYHA Class II heart failure: Resmetirom preferred. Pioglitazone is contraindicated in Class III-IV and carries risk even in Class II.
• Cost-constrained patient without insurance coverage for Rezdiffra: Generic pioglitazone at $30 to $120/year versus $47,400/year for Rezdiffra makes pioglitazone the only realistic option for many patients.

Combination Therapy and Emerging Approaches

Some hepatologists are exploring sequential or combination approaches: starting pioglitazone for insulin sensitization, then adding or switching to resmetirom for fibrosis-targeted therapy once it becomes accessible. No published trial has tested this combination, and additive GI or hepatic effects remain theoretical concerns. The mechanistic rationale (insulin sensitization plus enhanced hepatic fat oxidation) is sound, but safety data for the combination does not yet exist.

Patients currently on pioglitazone who transition to resmetirom should taper pioglitazone gradually rather than stopping abruptly, because sudden withdrawal of PPARγ activation can cause rebound hyperglycemia in diabetic patients. A 4 to 8 week taper with metabolic monitoring is a reasonable approach, though no guideline explicitly addresses this transition.

Resmetirom 80 mg daily is the recommended starting dose for patients weighing <100 kg, with 100 mg daily for those weighing ≥100 kg 7.